Cargando…
Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
AIMS: Early‐onset emphysema attributed to α‐1 antitrypsin deficiency (AATD) is frequently overlooked and undertreated. RAPID‐RCT/RAPID‐OLE, the largest clinical trials of purified human α‐1 proteinase inhibitor (A(1)‐PI; 60 mg kg(–1) week(–1)) therapy completed to date, demonstrated for the first ti...
Autores principales: | Tortorici, Michael A., Rogers, James A., Vit, Oliver, Bexon, Martin, Sandhaus, Robert A., Burdon, Jonathan, Chorostowska‐Wynimko, Joanna, Thompson, Philip, Stocks, James, McElvaney, Noel G., Chapman, Kenneth R., Edelman, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651313/ https://www.ncbi.nlm.nih.gov/pubmed/28662542 http://dx.doi.org/10.1111/bcp.13358 |
Ejemplares similares
-
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018) -
Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015) -
Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020) -
Targeted screening programmes in COPD: how to identify individuals with α(1)-antitrypsin deficiency
por: Chorostowska-Wynimko, Joanna
Publicado: (2015) -
Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)